Story · Medicine & Biotech

Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion

1 outlet · first reported by WSJ Health on

Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases. (WSJ Health)

Coverage, in order

  1. WSJ Health mainstream
    Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion

    Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.